Dynavax Technologies (NASDAQ:DVAX) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
A number of other equities research analysts also recently weighed in on DVAX. Royal Bank of Canada reissued an “outperform” rating and set a $28.00 price target (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cantor Fitzgerald boosted their price target on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. Finally, Cowen reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Three research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and an average target price of $25.17.
Shares of Dynavax Technologies (DVAX) opened at $15.42 on Friday. The firm has a market cap of $934.70, a P/E ratio of -7.87 and a beta of 1.31. Dynavax Technologies has a 12 month low of $3.70 and a 12 month high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. Dynavax Technologies’s revenue for the quarter was down 68.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.90) earnings per share. equities analysts anticipate that Dynavax Technologies will post -1.72 EPS for the current fiscal year.
In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the completion of the sale, the vice president now owns 7,780 shares of the company’s stock, valued at $144,708. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert Coffman sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC increased its position in shares of Dynavax Technologies by 54.5% during the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 3,700 shares in the last quarter. Legal & General Group Plc increased its position in shares of Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 1,950 shares in the last quarter. Wall Street Access Asset Management LLC bought a new stake in shares of Dynavax Technologies during the second quarter worth $124,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Dynavax Technologies by 474.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 5,880 shares in the last quarter. Finally, Family Management Corp increased its position in shares of Dynavax Technologies by 72.7% during the second quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 8,000 shares in the last quarter. 70.54% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/19/dynavax-technologies-dvax-stock-rating-lowered-by-bidaskclub.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.